2021
DOI: 10.1007/s40263-021-00821-0
|View full text |Cite
|
Sign up to set email alerts
|

The NOP Receptor System in Neurological and Psychiatric Disorders: Discrepancies, Peculiarities and Clinical Progress in Developing Targeted Therapies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
6
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(6 citation statements)
references
References 167 publications
0
6
0
Order By: Relevance
“…Unlike µ- and δ-opioid receptor subtypes, activation of ĸ-opioid and nociceptin opioid peptide (NOP) receptors are generally associated with a decrease in central monoaminergic activity (Gavioli and Calo, 2013; Schlicker and Morari, 2000; Tao and Auerbach, 2005; Yılmaz et al, 2006). It has also been suggested that agonists of ĸ- or NOP-receptors cause negative effects on mood (Ji et al, 2021; Toll et al, 2021), and blocking these receptors causes antidepressant-like effects (Jacobson et al, 2020; Park et al, 2019; Shang et al, 2021). Therefore, further studies are needed to clarify whether the antidepressant-like activity of tofisopam is associated with any attenuation in the functions of ĸ- and NOP-opioidergic receptors.…”
Section: Discussionmentioning
confidence: 99%
“…Unlike µ- and δ-opioid receptor subtypes, activation of ĸ-opioid and nociceptin opioid peptide (NOP) receptors are generally associated with a decrease in central monoaminergic activity (Gavioli and Calo, 2013; Schlicker and Morari, 2000; Tao and Auerbach, 2005; Yılmaz et al, 2006). It has also been suggested that agonists of ĸ- or NOP-receptors cause negative effects on mood (Ji et al, 2021; Toll et al, 2021), and blocking these receptors causes antidepressant-like effects (Jacobson et al, 2020; Park et al, 2019; Shang et al, 2021). Therefore, further studies are needed to clarify whether the antidepressant-like activity of tofisopam is associated with any attenuation in the functions of ĸ- and NOP-opioidergic receptors.…”
Section: Discussionmentioning
confidence: 99%
“…Nociceptin was first isolated and found to induce a decrease of latencies in hot plate and tail flick tests after intracerebroventricular injection in mice [41]. Later, it was discovered that nociceptin mediated the blocking of opioid-receptors-induced analgesia [42]. The nociceptins family have a Phe residue in the N-terminus, compared with the N-terminal Tyr in the other families of endogenous peptides (Figure 2), and participate in numerous biological activities, such as substance abuse, analgesia control, memory, posttraumatic stress disorder, neuronal differentiation, and cell proliferation [43][44][45].…”
Section: Nociceptinsmentioning
confidence: 99%
“…Nociceptin, a heptadecapeptide, binds and activates NOP, exhibiting a unique functional profile that relates to and distinguishes the receptor system from the considered classical opioid receptors (MOP, DOP, and KOP) [42,81,82]. Unlike the endogenous opioid peptides, a Phe residue, instead of Tyr, appears at its N-terminal end (Figure 2).…”
Section: The Nociceptin/orphanin Fq Receptor (Nop)mentioning
confidence: 99%
See 1 more Smart Citation
“…A major achievement was the identification of the nociceptin opioid peptide receptor (NOR), which in humans is encoded via the opioid receptor-like-1 (ORL-1) gene. It is a G protein-coupled receptor with homology to classical opioid receptors but it lacks the ability to bind opioid ligands [12]. NOR shares partial homology to MOR, KOR and DOR, and it is insensitive to opioid agonists, such as morphine.…”
Section: Introductionmentioning
confidence: 99%